Athanor Capital, LP Phathom Pharmaceuticals, Inc. Transaction History

Athanor Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$33.86 - $48.68 $557,741 - $801,856	-16,472 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$33.22 - $50.26 $2,258 - $3,417	-68 Reduced 0.41%	16,472 $547,000
Q3 2020 Nov 16, 2020	SELL	$29.24 - $40.19 $142,895 - $196,408	-4,887 Reduced 22.81%	16,540 $607,000
Q2 2020 Aug 13, 2020	BUY	$25.06 - $54.6 $536,960 - $1.17 Million	21,427 New	21,427 $705,000
Q1 2020 May 14, 2020	SELL	$24.65 - $42.83 $329,644 - $572,765	-13,373 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $248,604 - $503,760	13,373 New	13,373 $416,000

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $347M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.